clinical trial · NCT07573176
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC·phase3·not yet recruiting·n = 600
Depressive Disorder, MajorSeltorexantPlacebo
brief summary
The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.
started
May 4, 2026
primary completion
Aug 24, 2028
completion
May 3, 2029
last updated
May 7, 2026
official title
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol